Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks identifies Iovance Biotherapeutics as a potential earnings-surprise candidate ahead of its November 5, 2026 report: it has a #1 (Strong Buy) rank, an estimated loss of $0.07 per share versus consensus of $0.09, and +22.22% Earnings ESP. Recursion Pharmaceuticals is also flagged ahead of its November 4 report, with a #3 (Hold) rank and +2.82% ESP based on estimates of -$0.23 versus -$0.24 consensus. The article cites a historical 70% positive-surprise rate for stocks combining positive ESP with a Zacks Rank of #3 or better; neither company has yet reported results.

Analysis

The signal here is revisions positioning, not evidence of improving business fundamentals. IOVA’s cited $0.02/share gap is a narrower expected loss, not earnings growth; a positive ESP can therefore be directionally right on EPS while saying little about product demand, launch execution, or cash consumption. RXRX’s cited gap is smaller still, making a trade based on the headline percentage especially fragile. The article’s backtest statistics are promotional and do not establish returns net of event volatility, selection effects, or current market conditions.

Over the next days, both reports are binary catalysts: an EPS beat may be ignored if revenue, guidance, or operating commentary disappoints. For IOVA, verify commercial metrics and cash trajectory; for RXRX, focus on cash runway, partnership economics, and evidence that platform activity translates into fundable pipeline value. Over 1–3 months, estimate revisions and guidance matter more than the one-quarter EPS surprise. The structural risk is that investors pay for a favorable revision signal while underlying execution remains uncertain; a weaker outlook or financing concern could overwhelm a small beat. No competitive read-through is warranted from this article alone.

Key Decisions for Investors

• Do not buy either name solely on the ESP statistic. The negative EPS baselines make the quoted percentages easy to overread, and the article provides no corroboration from revenue or cash-flow estimates.
• Avoid an unhedged pre-earnings long in IOVA or RXRX; event gaps can dominate the potential benefit of a small consensus beat. Reassess after each report rather than treating the ESP as a standalone catalyst.
• Post-report, consider a small IOVA long only if any EPS beat is accompanied by constructive commercial metrics and no deterioration in cash outlook; exit or stay sidelined if guidance or cash consumption disappoints. For RXRX, require evidence of durable funding/partnership support rather than a marginally narrower loss.
• Track revenue, guidance, cash and runway commentary, and subsequent analyst revisions. A beat without improvement in those measures falsifies the bullish interpretation; a broad biotech selloff, observable in XBI, would also argue against taking single-name event risk.